During the last session, ITeos Therapeutics Inc (NASDAQ:ITOS)’s traded shares were 0.89 million, with the beta value of the company hitting 1.39. At the end of the trading day, the stock’s price was $11.26, reflecting an intraday gain of 0.36% or $0.04. The 52-week high for the ITOS share is $18.75, that puts it down -66.52 from that peak though still a striking 27.18% gain since the share price plummeted to a 52-week low of $8.20. The company’s market capitalization is $411.22M, and the average intraday trading volume over the past 10 days was 1.39 million shares, and the average trade volume was 495.81K shares over the past three months.

ITeos Therapeutics Inc (ITOS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ITOS has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.89.

ITeos Therapeutics Inc (NASDAQ:ITOS) trade information

ITeos Therapeutics Inc (ITOS) registered a 0.36% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.36% in intraday trading to $11.26, hitting a weekly high. The stock’s 5-day price performance is -32.57%, and it has moved by -35.69% in 30 days. Based on these gigs, the overall price performance for the year is -8.01%. The short interest in ITeos Therapeutics Inc (NASDAQ:ITOS) is 2.61 million shares and it means that shorts have 9.04 day(s) to cover.

The consensus price target of analysts on Wall Street is $36, which implies an increase of 68.72% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $31 and $46 respectively. As a result, ITOS is trading at a discount of -308.53% off the target high and -175.31% off the low.

ITeos Therapeutics Inc (ITOS) estimates and forecasts

Statistics show that ITeos Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. ITeos Therapeutics Inc (ITOS) shares have gone down -1.23% during the last six months, with a year-to-date growth rate less than the industry average at -15.56% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 1.10% this quarter and then drop -61.20% in the quarter after that. In the rating firms’ projections, revenue will increase 263.90% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 16.67M as predicted by 6 analyst(s).

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -40.62%. While earnings are projected to return -13.94% in 2024.

ITOS Dividends

ITeos Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

ITeos Therapeutics Inc (NASDAQ:ITOS)’s Major holders

ITeos Therapeutics Inc insiders own 0.70% of total outstanding shares while institutional holders control 102.77%, with the float percentage being 103.49%. BLACKROCK INC. is the largest shareholder of the company, while 210.0 institutions own stock in it. As of 2024-06-30, the company held over 3.73 million shares (or 10.4094% of all shares), a total value of $55.37 million in shares.

The next largest institutional holding, with 3.52 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 9.8129% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $52.2 million.